Legalization trend drives cannabis ETFs to significantly grow
More and more US states are legalizing the use of cannabis. The trend around the plant is not only boosting individual stocks from the cannabis sector, which is characterized by mergers and acquisitions, but also ETFs that track the sector. While cannabis ETFS have seen a significant jump in prices since the beginning of the year, their performance has been anything but stable.
After stocks such as GameStop and AMC were catapulted to unimagined price heights in the Reddit community “WallStreetBets” in January, online users had set their sights on a new target in early February with numerous cannabis stocks. But even before the net hype, the prices of stocks like Tilray, Aphria, Canopy Growth, and Aurora Cannabis jumped, making the industry another major trending topic on the stock market, as also reported by Deutsche Presse-Agentur.
The increased demand for the industry is not only noticeable in individual stocks, but also in corresponding investment funds. For example, the three best-performing ETFs this year all have in common that they track the cannabis industry, according to a report by Bloomberg. According to the news agency’s analysis, the Global X Cannabis ETF, the Cannabis ETF (THCX), and the Amplify SeymourCannabis ETF have already posted returns of more than 90 percent year-to-date, significantly outperforming the S&P 500.
Read the latest cannabis news in the world with the Hemp.im mobile app.
Legalization well underway in the U.S.
Strong stock price gains are also raising hopes that cannabis will soon be legalized in the U.S., Bloomberg further reported. For example, Andrew Cuomo, the governor of New York, recently came out in favor of legalizing cannabis in his state, he said. He added that the Democratic majority in Congress is also optimistic about approval.
According to a November 2020 NBC evaluation, cannabis may be used for recreational purposes in 15 U.S. states. Medical use is allowed in a total of 34 states. If more states follow suit here, this could significantly boost demand, according to Todd Rosenbluth of CFRA Research, making cannabis companies significantly more profitable. But the industry can also benefit from rising expectations for company earnings growth and a large number of mergers and acquisitions, according to Bloomberg analyst Kenneth Shea.
Tilray and Aphria impress with strong sales figures after merger announcement
Currently, the most popular example of the merger wave in the cannabis industry is the merger of industry giants Tilray and Aphria. In December 2020, the companies announced the merger, which is expected to be completed in the second quarter of 2021 and give the two a combined market share of nearly 20 percent. Tilray and Aphria also became targets of recent Reddit hype, according to Bloomberg, but also have strong quarterly results to thank for their share price breakouts.
While Aphria already presented its financial statements for the second fiscal quarter that ended at the end of November in January, exceeding analysts’ expectations, Tilray thrilled investors in mid-February with sales figures for the fourth fiscal quarter of 2020 that exceeded experts’ outlooks. Both companies subsequently benefited from rising share prices. They not only make up a large portion of the Global X Cannabis ETF, but also the billion-dollar ETFMG AlternativeHarvest ETF.
Canopy Growth and Aurora Cannabis also in demand
Shortly before, competitor Canopy Growth also presented figures. The Canadian cannabis company suffered a significant loss per share in its most recent third quarter, but was able to score in terms of sales and even exceeded analysts’ estimates.
At Aurora Cannabis, meanwhile, the loss was lower than expected, but in terms of sales, the competitor fell short of expert expectations. Both companies are also included in the Global X Cannabis ETF.
Industry characterized by high volatility
While cannabis ETFS have seen a significant jump in prices since the beginning of the year, their performance has been anything but stable, as Bloomberg summarizes. For example, while funds have risen in 2018 after the legal situation in Canada and the U.S. partially loosened, cannabis producers have subsequently struggled with low returns, seen as a result of weak quarterly reports, a slow legalization process, and difficulties in assembling product portfolios.
“It seems like the cannabis space is a whirlwind: You can have some great return periods and others that are more difficult,” UBS strategist for ETFs David Perlman also believes. “It’s an area where you have to expect volatility, and you really have to look at the ETF to make sure you’re getting the names you want.”
(Featured image by StockSnap via Pixabay)
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in finanzen.net, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Adult-Use Cannabis Could Soon Be Legalized in Colombia
Colombia is one step closer to the legalization of adult-use cannabis. Many parliamentarians who were previously fervently opposed to the...
Why Ripple Registered a 29% Weekly Increase
The number of daily transactions on Ripple recently reached 2.3 million, the highest in 16 months. At the same time,...
Moderna Will Pay $70 Million to Generation Bio for Genetic Medicines
Moderna closed 2022 with a profit of $8.36 billion, which represents a decrease of 31% compared to the previous year....
Cotton Demand Has Been Ramping Up for the Last Couple of Months but Fell Off
Cotton was lower and closed at new lows for the move. Chart trends turned down again with the price action...
The US Equity Crowdfunding Platform WeFunder Launches in Europe
Unlike the other platforms, WeFunder has taken a "soft" approach compared to, for example, Republic's $100 million acquisition of Seedrs,...
Cannabis6 days ago
Trichome Pharma Prepares a Greenhouse in Andalusia to Grow Medical Cannabis
Business2 weeks ago
No Major Spanish Bank Was Affected by Credit Suisse’s Collapse
Crowdfunding2 days ago
The US Equity Crowdfunding Platform WeFunder Launches in Europe
Cannabis1 week ago
Grünhorn Becomes Sponsor of the Leipzig Kings